ALS Clinical Trials | ALS Therapy Development Institute

The ALS Therapy Development Institute (ALS TDI) is unbiased in our listing of clinical trials and provides information on all those enrolling worldwide.

We encourage you to browse trials below and subscribe to our clinical trials email to receive monthly updates with changes to trials listed in this database.

In early 2024, ALS TDI looks forward to unveiling our innovative new resource – the ALS Trial Navigator! Subscribe to our emails to be the first to access this cutting-edge platform.

Currently Enrolling Clinical Trials

List includes only interventional trials with locations in the US.

RAPA-501 Therapy for ALS

Phase 2/3 - Recruiting

Enrollment: 41

Drug: RAPA-501 Autologous T cells

Type: Interventional

Open Label: No

Countries: US

Learn More

Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial

Phase 2 - Recruiting

Enrollment: 60

Drug: Combination Antioxidants

Type: Interventional

Open Label: Unknown

Countries: United States

Learn More

Adenosine 2A Receptor Antagonism and AIH in ALS

Phase 1/2 - Recruiting

Enrollment: 40

Drug: Unknown

Type: Interventional

Open Label: No

Countries: US, United States

Learn More

Safety, Tolerability, and Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Amyotrophic Lateral Sclerosis (ALS) Patients With SOD1 Mutations

Phase 1/2 - Recruiting

Enrollment: 20

Drug: Unknown

Type: Interventional

Open Label: Yes

Countries: United States

Learn More

RAPA-501 Therapy for ALS EAP

N/A - Available

Enrollment: 40

Drug: Unknown

Type: Expanded Access

Open Label:

Countries: US

Learn More

Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS

Phase EAP - Available

Enrollment: N/A

Drug: Unknown

Type: Expanded Access

Open Label:

Countries: US

Learn More

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

Phase 2 - Recruiting

Enrollment: 225

Drug: Unknown

Type: Interventional

Open Label: Yes

Countries: Australia, Belgium, Canada, China, Denmark, France, Germany, Ireland, Japan, Netherlands, Poland, South Korea, Spain, Sweden, Switzerland, United Kingdom, United States

Learn More

A Study of Ranolazine in ALS

Phase 2 - Recruiting

Enrollment: 72

Drug: Unknown

Type: Interventional

Open Label: Unknown

Countries: United States

Learn More

Trial of Oral Digoxin in Individuals With Amyotrophic Lateral Sclerosis (ALS)

Phase 2 - Recruiting

Enrollment: 40

Drug: Unknown

Type: Interventional

Open Label:

Countries: US

Learn More

A Study of STRO4 in Patients Amyotrophic Lateral Sclerosis (ALS)

Phase 2 - Recruiting

Enrollment: 9

Drug: Unknown

Type: Interventional

Open Label:

Countries: United States

Learn More

RAPA-501 Therapy for ALS

Phase 2/3 - Recruiting

Enrollment: 41

Drug: RAPA-501 Autologous T cells

Type: Interventional

Open Label: No

Countries: US

Learn More

Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial

Phase 2 - Recruiting

Enrollment: 60

Drug: Combination Antioxidants

Type: Interventional

Open Label: Unknown

Countries: United States

Learn More

Adenosine 2A Receptor Antagonism and AIH in ALS

Phase 1/2 - Recruiting

Enrollment: 40

Drug: Unknown

Type: Interventional

Open Label: No

Countries: US, United States

Learn More

Safety, Tolerability, and Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Amyotrophic Lateral Sclerosis (ALS) Patients With SOD1 Mutations

Phase 1/2 - Recruiting

Enrollment: 20

Drug: Unknown

Type: Interventional

Open Label: Yes

Countries: United States

Learn More

RAPA-501 Therapy for ALS EAP

N/A - Available

Enrollment: 40

Drug: Unknown

Type: Expanded Access

Open Label:

Countries: US

Learn More

Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS

Phase EAP - Available

Enrollment: N/A

Drug: Unknown

Type: Expanded Access

Open Label:

Countries: US

Learn More

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

Phase 2 - Recruiting

Enrollment: 225

Drug: Unknown

Type: Interventional

Open Label: Yes

Countries: Australia, Belgium, Canada, China, Denmark, France, Germany, Ireland, Japan, Netherlands, Poland, South Korea, Spain, Sweden, Switzerland, United Kingdom, United States

Learn More